Cover Image
市場調查報告書

Regulus Therapeutics Inc.:產品平台分析

Regulus Therapeutics Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253752
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
Regulus Therapeutics Inc.:產品平台分析 Regulus Therapeutics Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 40 Pages
簡介

Regulus Therapeutics Inc.ha,是利用微型核糖核酸來開發治療藥的生物醫藥品企業。

本報告提供Regulus Therapeutics Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

Regulus Therapeutics Inc.的基本資料

  • Regulus Therapeutics Inc.概要
  • 主要資訊
  • 企業資料

Regulus Therapeutics Inc.:R&D概要

  • 主要的治療範圍

Regulus Therapeutics Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Regulus Therapeutics Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ階段的產品/聯合治療模式
    • 第Ⅰ階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Regulus Therapeutics Inc.:藥物簡介

  • RG-101
  • RG-012
  • Antisense RNAi Oligonucleotide to Inhibit MicroRNA-10b for Metastatic Breast Cancer and Glioblastoma Multiforme
  • Antisense RNAi Oligonucleotide to Inhibit MicroRNA-21 for Hepatocellular Carcinoma
  • Antisense RNAi Oligonucleotide to Inhibit miR-221 and miR-222 for Hepatocellular Carcinoma
  • Antisense RNAi Oligonucleotides for Oncology and Orphan Diseases
  • RG-125
  • Antisense RNAi Oligonucleotide to Inhibit MicroRNA for Metabolic Disease

Regulus Therapeutics Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Regulus Therapeutics Inc.:最近的開發平台趨勢

Regulus Therapeutics Inc.:暫停中的計劃

Regulus Therapeutics Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • Anti microRNA-33a/b

Regulus Therapeutics Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07528CDB

Summary

Global Markets Direct's, 'Regulus Therapeutics Inc. - Product Pipeline Review - 2015', provides an overview of the Regulus Therapeutics Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Regulus Therapeutics Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Regulus Therapeutics Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Regulus Therapeutics Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Regulus Therapeutics Inc.'s pipeline products

Reasons to buy

  • Evaluate Regulus Therapeutics Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Regulus Therapeutics Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Regulus Therapeutics Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Regulus Therapeutics Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Regulus Therapeutics Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Regulus Therapeutics Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Regulus Therapeutics Inc. Snapshot
    • Regulus Therapeutics Inc. Overview
    • Key Information
    • Key Facts
  • Regulus Therapeutics Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Regulus Therapeutics Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Regulus Therapeutics Inc. - Pipeline Products Glance
    • Regulus Therapeutics Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Regulus Therapeutics Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Regulus Therapeutics Inc. - Drug Profiles
    • RG-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-012
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit MicroRNA-10b for Metastatic Breast Cancer and Glioblastoma Multiforme
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit MicroRNA-21 for Hepatocellular Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit miR-221 and miR-222 for Hepatocellular Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides for Oncology and Orphan Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-125
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit MicroRNA for Metabolic Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Regulus Therapeutics Inc. - Pipeline Analysis
    • Regulus Therapeutics Inc. - Pipeline Products by Target
    • Regulus Therapeutics Inc. - Pipeline Products by Route of Administration
    • Regulus Therapeutics Inc. - Pipeline Products by Molecule Type
    • Regulus Therapeutics Inc. - Pipeline Products by Mechanism of Action
  • Regulus Therapeutics Inc. - Recent Pipeline Updates
  • Regulus Therapeutics Inc. - Dormant Projects
  • Regulus Therapeutics Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
  • Antisense RNAi Oligonucleotide to Inhibit MicroRNA-19 for Cancer
  • Regulus Therapeutics Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Regulus Therapeutics Inc., Key Information
  • Regulus Therapeutics Inc., Key Facts
  • Regulus Therapeutics Inc. - Pipeline by Indication, 2015
  • Regulus Therapeutics Inc. - Pipeline by Stage of Development, 2015
  • Regulus Therapeutics Inc. - Monotherapy Products in Pipeline, 2015
  • Regulus Therapeutics Inc. - Phase II, 2015
  • Regulus Therapeutics Inc. - Phase I, 2015
  • Regulus Therapeutics Inc. - Preclinical, 2015
  • Regulus Therapeutics Inc. - Discovery, 2015
  • Regulus Therapeutics Inc. - Pipeline by Target, 2015
  • Regulus Therapeutics Inc. - Pipeline by Route of Administration, 2015
  • Regulus Therapeutics Inc. - Pipeline by Molecule Type, 2015
  • Regulus Therapeutics Inc. - Pipeline Products by Mechanism of Action, 2015
  • Regulus Therapeutics Inc. - Recent Pipeline Updates, 2015
  • Regulus Therapeutics Inc. - Dormant Developmental Projects,2015
  • Regulus Therapeutics Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Regulus Therapeutics Inc. - Pipeline by Top 10 Indication, 2015
  • Regulus Therapeutics Inc. - Pipeline by Stage of Development, 2015
  • Regulus Therapeutics Inc. - Monotherapy Products in Pipeline, 2015
  • Regulus Therapeutics Inc. - Pipeline by Top 10 Target, 2015
  • Regulus Therapeutics Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Regulus Therapeutics Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Regulus Therapeutics Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top